HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adrian M Di Bisceglie Selected Research

Hepatitis B e Antigens

6/2023Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.
1/2023Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
1/2023Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial.
1/2021Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
11/2019Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.
11/2019Phenotypes of Chronic Hepatitis B in Children From a Large North American Cohort.
11/2019Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia.
1/2019Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.
12/2007Telbivudine versus lamivudine in patients with chronic hepatitis B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Adrian M Di Bisceglie Research Topics

Disease

57Fibrosis (Cirrhosis)
01/2023 - 11/2002
47Infections
02/2024 - 03/2002
39Hepatitis C
01/2021 - 11/2002
35Chronic Hepatitis C
01/2020 - 11/2002
27Hepatocellular Carcinoma (Hepatoma)
11/2019 - 05/2002
23Liver Diseases (Liver Disease)
06/2023 - 11/2002
10Chronic Hepatitis B
06/2023 - 12/2007
10Neoplasms (Cancer)
01/2021 - 05/2002
8Hepatitis B
06/2023 - 05/2009
7Liver Cirrhosis (Hepatic Cirrhosis)
09/2013 - 03/2005
5End Stage Liver Disease
06/2021 - 07/2005
5Virus Diseases (Viral Diseases)
02/2015 - 11/2004
4Viremia
06/2023 - 10/2004
4Fatty Liver
01/2021 - 01/2003
3Inflammation (Inflammations)
06/2021 - 01/2003
3Ascites
06/2021 - 11/2005
3Body Weight (Weight, Body)
12/2010 - 10/2008
3Varicose Veins (Varicose Vein)
06/2010 - 11/2005
3Hemorrhage
01/2010 - 12/2003
3Disease Progression
11/2009 - 10/2004
2Hepatitis
01/2021 - 10/2004
2Non-alcoholic Fatty Liver Disease
01/2021 - 01/2003
2Weight Loss (Weight Reduction)
01/2021 - 12/2010
2Hyperlipidemias (Hyperlipidemia)
11/2020 - 11/2019
2Substance-Related Disorders (Drug Abuse)
01/2020 - 01/2017
2Reinfection
01/2016 - 04/2004
2Anemia
06/2011 - 12/2003
2Persistent Infection
05/2011 - 03/2003
2Fever (Fevers)
05/2010 - 12/2003
2Coinfection
01/2010 - 04/2005
2Necrosis
12/2003 - 01/2003
2Superinfection
07/2003 - 09/2002
1Acute Liver Failure (Fulminant Hepatic Failure)
02/2024
1Sclerosing Cholangitis
11/2022
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/2022
1Alcoholic Fatty Liver
01/2021
1Type 2 Diabetes Mellitus (MODY)
01/2021
1Thrombotic Stroke
11/2020
1Myocardial Infarction
11/2020

Drug/Important Bio-Agent (IBA)

46Antiviral Agents (Antivirals)IBA
02/2024 - 11/2002
32Ribavirin (Virazole)FDA LinkGeneric
02/2016 - 11/2002
24InterferonsIBA
02/2016 - 01/2004
11Biomarkers (Surrogate Marker)IBA
06/2021 - 06/2009
10Proteins (Proteins, Gene)FDA Link
06/2021 - 06/2009
9Hepatitis B Surface Antigens (HBsAg)FDA Link
06/2023 - 08/2011
9Hepatitis B e AntigensIBA
06/2023 - 12/2007
9RNA (Ribonucleic Acid)IBA
12/2016 - 04/2004
8peginterferon alfa-2a (Pegasys)FDA Link
06/2011 - 04/2004
7DNA (Deoxyribonucleic Acid)IBA
01/2023 - 05/2009
6BilirubinIBA
01/2021 - 11/2005
6Alanine Transaminase (SGPT)IBA
01/2021 - 03/2009
6Complement System Proteins (Complement)IBA
01/2016 - 03/2002
5AlbuminsIBA
01/2020 - 01/2010
5SofosbuvirIBA
12/2016 - 04/2014
5alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2013 - 09/2005
4telaprevirIBA
07/2014 - 04/2010
4Interferon-alpha (Interferon Alfa)IBA
06/2009 - 01/2004
3BerberineIBA
11/2022 - 11/2020
3Ursodeoxycholic Acid (Urso)FDA LinkGeneric
11/2022 - 11/2005
3MicroRNAs (MicroRNA)IBA
10/2017 - 09/2013
3ledipasvirIBA
12/2016 - 04/2014
3Glycoproteins (Glycoprotein)IBA
07/2013 - 03/2002
3Messenger RNA (mRNA)IBA
07/2013 - 05/2011
3Kininogens (Kininogen)IBA
01/2013 - 06/2009
3Neutralizing AntibodiesIBA
04/2006 - 03/2002
2Hepatitis B Core AntigensIBA
06/2023 - 02/2015
2Tenofovir (Viread)FDA Link
01/2023 - 01/2023
2NucleotidesIBA
01/2023 - 05/2014
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2021 - 01/2010
2EnzymesIBA
01/2021 - 01/2003
2sofosbuvir drug combination ledipasvirIBA
12/2016 - 05/2014
2Rituximab (Mabthera)FDA Link
02/2015 - 05/2010
2AntibodiesIBA
01/2013 - 03/2002
2Polysaccharides (Glycans)IBA
06/2011 - 08/2010
2Transaminases (Aminotransferases)IBA
05/2010 - 04/2006
2Lamivudine (Epivir)FDA Link
01/2010 - 12/2007
2IronIBA
06/2007 - 11/2006
1Viral AntigensIBA
06/2023
1Viral DNAIBA
06/2023
1Lipopolysaccharide ReceptorsIBA
06/2021
1Immunoglobulins (Immunoglobulin)IBA
06/2021
1Anti-Bacterial Agents (Antibiotics)IBA
06/2021
1lipopolysaccharide-binding proteinIBA
06/2021
1Lactulose (Duphalac)FDA LinkGeneric
06/2021
1Fatty Acid-Binding ProteinsIBA
06/2021
1clonidine-displacing substance (ClDS)IBA
01/2021
1SaltsIBA
01/2021
1LDL CholesterolIBA
11/2020
18- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA
11/2020

Therapy/Procedure

56Therapeutics
02/2024 - 11/2002
16Liver Transplantation
01/2021 - 05/2002
4Aftercare (After-Treatment)
06/2021 - 11/2004
4Retreatment
04/2014 - 11/2006
4Transplantation
10/2011 - 04/2004
2Bone Marrow Transplantation (Transplantation, Bone Marrow)
11/2019 - 10/2011
2Duration of Therapy
02/2016 - 12/2010
2Drug Therapy (Chemotherapy)
02/2015 - 05/2010
2Stents
06/2005 - 12/2003
2Transjugular Intrahepatic Portasystemic Shunt
06/2005 - 12/2003
1Glycemic Control
01/2021